Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17316422 | 0.88 | TRPV4 (0.52) | TRPV4 | |
| SCHEMBL26074105 | 0.79 | TRPV4 (0.39) | TRPV4CYP1A2CYP2C19 | |
| SCHEMBL28341814 | 0.79 | TRPV4 (0.44) | TRPV4 | |
| SCHEMBL31114192 | 0.79 | TRPV4 (0.36) | TRPV4 | |
| SCHEMBL22802480 | 0.77 | CACNA1H (0.39) | TRPV4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16680760 | 0.75 | TRPV4 (0.46) | TRPV4CYP1A2CYP2C19NPSR1 | |
| SCHEMBL425826 | 0.75 | TRPV4 (0.46) | TRPV4 | |
| SCHEMBL19660562 | 0.75 | TRPV4 (0.33) | TRPV4 | |
| SCHEMBL20095954 | 0.73 | TRPV4 (0.34) | TRPV4 | |
| SCHEMBL31535947 | 0.73 | TRPV4 (0.34) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4299135-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | PFIZER INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3986890-B9 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-114364672-B | Benzisoxazole sulfonamide derivatives | 辉瑞大药厂 | 2024-09-06 | — | — | CN | disclosed |
| EP-4299135-A2 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | Pfizer Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3986890-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3986890-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | MONASH UNIVERSITY (AU) | 2023-06-08 | — | — | US | disclosed |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | MONASH UNIVERSITY (AU) | 2023-06-08 | — | — | US | disclosed |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | MONASH UNIVERSITY (AU) | 2023-06-08 | — | — | US | disclosed |
| US-11492346-B2 | Benzisoxazole sulfonamide derivatives | PFIZER INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3986890-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | Pfizer Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114364672-A | Benzisoxazole sulfonamide derivatives | 辉瑞大药厂 | 2022-04-15 | — | — | CN | disclosed |
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER INC. | 2020-12-24 | — | — | US | disclosed |
| WO-2020254946-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254946-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER INC. | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | BRIX1, RB1, BCR | TRPV4 2910/4885CYP1A2 858/4885CYP2D6 1087/4885 |
| US-20200399258-A1 | Benzisoxazole Sulfonamide Derivatives | BRIX1, RB1, BCR | TRPV4 2837/4885CYP1A2 810/4885CYP2D6 1066/4885 |
| US-11492346-B2 | Benzisoxazole sulfonamide derivatives | BRIX1, RB1, BCR | TRPV4 2910/4885CYP1A2 858/4885CYP2D6 1087/4885 |
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | KAT8, KAT5, KAT7 | TRPV4 3638/4885CYP1A2 1605/4885CYP2D6 1283/4885 |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | BRIX1, RB1, BCR | TRPV4 2910/4885CYP1A2 858/4885CYP2D6 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.